-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Relmada Therapeutics, Raises Price Target to $19

Benzinga·03/20/2026 13:44:05
Listen to the news
Mizuho analyst Uy Ear maintains Relmada Therapeutics (NASDAQ:RLMD) with a Outperform and raises the price target from $10 to $19.